| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- (±)-Lisofylline
-
- $33.00
-
2026-07-27
- CAS:6493-06-7
- Purity: 99.91%
- Supply Ability: 10g
|
| | Hydroxy pentoxifylline Basic information | | Synthesis |
| | Hydroxy pentoxifylline Chemical Properties |
| Melting point | 123-125°C | | Boiling point | 511.2±56.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | DMSO: soluble | | form | solid | | pka | 15.22±0.20(Predicted) | | color | white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. | | InChI | InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3 | | InChIKey | NSMXQKNUPPXBRG-UHFFFAOYSA-N | | SMILES | N1(C)C2=C(N(C)C(=O)N(CCCCC(O)C)C2=O)N=C1 |
| | Hydroxy pentoxifylline Usage And Synthesis |
| Synthesis | In an anhydrous and oxygen-free glove box, cobalt complex (0.005–0.04 mmol, 0.5–4 mol%) or an in-situ cobalt carbene catalytic system [i.e., a mixture of CoCl2 (0.005–0.04 mmol, 0.5–4 mol%) and a 3-aza-heterocyclic carbene ligand (0.005–0.04 mmol, 0.5–4 mol%)] and an appropriate amount of base (0.05–0.2 mmol, 5–20 mol%) were added to a 4 mL glass reaction flask containing a magnetic stir bar, followed by 0.5 mL of solvent, and finally the substrate (1 mmol). After shaking for 30 seconds, the mixture was transferred to a ParrInstruments high-pressure reactor. After removing the high-pressure reactor from the glove box, hydrogen gas at 10–30 bar was introduced, and the reaction temperature was set at 25–60 °C for 16 hours. After the reaction was stopped, the high-pressure reactor was first cooled in a 0 °C ice-water bath, and then the hydrogen gas inside the reactor was slowly released. The reaction flask was removed from the high-pressure reactor, and the product HYDROXY PENTOXIFYLLINE was separated by rapid column chromatography and weighed to obtain the yield. | | Description | Lisofylline (6493-06-7, racemic) displays anti-inflammatory activity. Regulates immune cell function and autoimmune response by inhibition of IL-12 signalling and cytokine production.1 Protects pancreatic beta cells and prevents type I diabetes in non-obese diabetic mice.2 Lisofylline reduces LPS-induced TNF alpha levels in CD-1 mice.3Cell permeable. | | Chemical Properties | White Solid | | Uses | A major oxidative metabolite of Pentoxifylline. A potent inhibitor of phosphatidic acid generation (IC50=0.6uM). Protects mice from endotoxic shock and attenuates sepsis-induced acute lung injury in pig. | | Definition | ChEBI: 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione is a dimethylxanthine that is 3,7-dihydro-1H-purine-2,6-dione which is substituted at positions 1,3 and 7 by a 5-hydroxyhexyl group, methyl group and methyl group, respectively. It is a secondary alcohol and a dimethylxanthine. | | Brand name | ProTec (Cell
Therapeutics). | | in vitro | (±)-lisofylline is a potent anti-inflammatory agent in which only the (-) optical isomer is biologically active. (±)-lisofylline was found to inhibit the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase. (±)-lisofylline could also suppress the production of the proinflammatory cytokine ifn-γ, inhibit il-12-mediated stat-4 activation, as well as enhance glucose-stimulated β-cell insulin secretion [1]. | | in vivo | in a previous study, lisofylline was administered to female non-obese diabetic mice for 3 weeks. cytokines and blood glucose concentrations were monitored. histology and immunohistochemistry were also carried out in pancreatic sections. results showed that lisofylline was able to suppress ifn-γ production, reduce the onset of insulitis and diabetes, and inhibit diabetes [1]. | | References | [1] ZANDONG YANG Jerry L N Meng Chen. Lisofylline: a potential lead for the treatment of diabetes[J]. Biochemical pharmacology, 2005, 69 1: Pages 1-5. DOI:10.1016/j.bcp.2004.08.012
[2] Z-D YANG. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.[J]. Diabetologia, 2002, 45 9: 1307-1314. DOI:10.1007/s00125-002-0901-y
[3] WYSKA E. Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide.[J]. Pharmacology, 2010, 85 5: 264-271. DOI:10.1159/000288734 |
| | Hydroxy pentoxifylline Preparation Products And Raw materials |
|